Trace Biosciences Receives Strategic Investment from Axogen for Nerve Imaging Technology
Clinical-stage biotechnology company Trace Biosciences announced a strategic investment from Axogen. The funding will advance the clinical development of its nerve-specific imaging technology.
PORTLAND, Ore., July 29, 2026 – Trace Biosciences, Inc., a clinical-stage biotechnology company developing nerve-targeted imaging agents, has received a strategic investment from Axogen, Inc. (NASDAQ: AXGN), a global leader in surgical solutions for nerve repair.
The investment is intended to accelerate the ongoing clinical development of Trace Biosciences' nerve-specific imaging technology, known as Nerve Trace. This technology aims to assist surgeons in identifying and visualizing peripheral nerves during surgical procedures, with the goal of improving surgical outcomes and reducing the risk of nerve damage.
Trace Biosciences has been developing the technology in collaboration with several leading academic medical centers. The capital infusion from Axogen will support the evaluation of preclinical endpoints and enable preparations for future clinical studies.
Axogen's CEO stated that the investment aligns with the company's strategy to provide surgeons with the best possible tools for nerve surgery. The Trace Biosciences technology is expected to complement Axogen's existing portfolio.